ABT-263

ABT-263 

To Order Contact us: caitlyn@ucb-bioproducts.com

ABT-263 (Navitoclax)

A3007-100 100 mg
EUR 456
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-1000 1 g
EUR 3298
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-5 5 mg
EUR 108
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-5.1 10 mM (in 1mL DMSO)
EUR 166
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-50 50 mg
EUR 282
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-S Evaluation Sample
EUR 81
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT

B7737-5.1 10 mM (in 1mL DMSO)
EUR 108

ABT

B7737-50 50 mg
EUR 125

ABT-737

2463-25
EUR 675

ABT-737

2463-5
EUR 207

ABT-869

1615-1
EUR 213

ABT-869

1615-5
EUR 615

ABT-888

1620-1
EUR 218

ABT-888

1620-5
EUR 615

ABT-494

B1947-25
EUR 892

ABT-494

B1947-5
EUR 262

Abt-199

abx184638-1g 1 g
EUR 648
  • Shipped within 1-2 weeks.

Abt-869

20-abx182361
  • EUR 1803.00
  • EUR 551.00
  • 100 mg
  • 10 mg
  • Shipped within 1-2 weeks.

ABT-737

E1KS1002 5mg
EUR 521

ABT-751

E1KS1165 10mg
EUR 521

ABT-492

E1KS1553 5mg
EUR 1111

ABT-737

A8193-10 10 mg
EUR 154
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-100 100 mg
EUR 606
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-5 5 mg
EUR 108
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-5.1 10 mM (in 1mL DMSO)
EUR 148
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-50 50 mg
EUR 398
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-500 500 mg
EUR 1558
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-737

A8193-S Evaluation Sample
EUR 81
Description: ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-XL, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1.

ABT-199

A8194-1 1 mg
EUR 131
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-5 5 mg
EUR 270
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-5.1 10 mM (in 1mL DMSO)
EUR 421
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-50 50 mg
EUR 838
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-500 500 mg
EUR 1442
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-S Evaluation Sample
EUR 81
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-239

HY-12195 10mg
EUR 337

ABT-751

HY-13270 50mg
EUR 394

ABT-046

HY-15197 10mM/1mL
EUR 420

ABT-670

HY-19483 1mg
EUR 849

ABT-639

HY-19721 100mg
EUR 2943

ABT-737

HY-50907 10mM/1mL
EUR 155

ABT-072

HY-101634 10mg
EUR 1399

Sulfo-Cyanine 3 NHS ester

263 10 mg
EUR 480
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12171501

Zotarolimus(ABT-578)

B4786-25 25 mg
EUR 741
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug.

Zotarolimus(ABT-578)

B4786-5 5 mg
EUR 347
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug.

ABT 702 dihydrochloride

B5298-10 10 mg
EUR 412
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-100 100 mg
EUR 1708
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-5 5 mg
EUR 276
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-5.1 10 mM (in 1mL DMSO)
EUR 316
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-50 50 mg
EUR 1181
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

Paritaprevir(ABT-450)

20-abx184297
  • EUR 1247.00
  • EUR 913.00
  • 10 mg
  • 5 mg
  • Shipped within 1-2 weeks.

Linifanib (ABT-869)

E1KS1003 5mg
EUR 521

ABT-888 (Veliparib)

E1KS1004 5mg
EUR 325

Lopinavir(ABT-378)

E1KS1380 10mg
EUR 403

ABT 724 trihydrochloride

B6981-10 10 mg
EUR 308
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05).

ABT 724 trihydrochloride

B6981-50 50 mg
EUR 1136
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05).

Linifanib (ABT-869)

A2949-100 100 mg
EUR 780
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

ABT-263